Hyderabad News Desk

The Anaplastic Astrocytoma Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Anaplastic Astrocytoma treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Anaplastic Astrocytoma pipeline landscape and fostering the potential growth of Anaplastic Astrocytoma therapeutic advancements.

Key Takeaways from the Anaplastic Astrocytoma Pipeline Report

• DelveInsight’s Anaplastic Astrocytoma pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Anaplastic Astrocytoma treatment.
• The leading companies working in the Anaplastic Astrocytoma Market include Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm Inc., OncoSynergy, AEterna Zentaris, Oncoceutics, DNAtrix, Novartis Pharmaceuticals, Curis, Inc., Everfront Biotech Co., Ltd., Pfizer, Kazia Therapeutics Limited, Bayer, Geneos Therapeutics, Cellix Bio, Mustang Bio, Deciphera Pharmaceuticals, Aveta Biomics, and others.
• Promising Anaplastic Astrocytoma Pipeline Therapies in the various stages of development include Eflornithine, Lomustine, Erlotinib, Sunitinib Malate, Bononophenylalanine (BPA)-based BNCT, Leflunomide, LS11 (talaporfin sodium), Temozolomide, Semustine, CC-90010, AP 12009 10 µM, TG02, AMG 595, Valacyclovir, and others.
• On June 2023, Celgene announced a study of Phase 1 Clinical Trials for CC-90010. CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive or recurrent WHO Grade II Diffuse Astrocytoma, Grade III Anaplastic Astrocytoma and recurrent Glioblastoma who have failed radiation and chemotherapy, and who are candidates for surgical tumor resection as part of their salvage regimen (planned salvage resection).
• On August 2023, Candel Therapeutics Inc. announced a study of Phase 1 Clinical Trias for AdV-tk and Valacyclovir. This phase I study evaluated a Gene Mediated Cytotoxic Immunotherapy approach for malignant gliomas, including glioblastoma multiforme and anaplastic astrocytoma. The purpose of this study was to assess the safety and feasibility of delivering an experimental approach called GliAtak which uses AdV-tk, an adenoviral vector containing the Herpes Simplex thymidine kinase gene, plus an oral anti-herpetic prodrug, valacyclovir, in combination with standard of care radiation.

Request a sample and discover the recent advances in Anaplastic Astrocytoma Treatment Drugs @ Anaplastic Astrocytoma Pipeline Report

The Anaplastic Astrocytoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anaplastic Astrocytoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anaplastic Astrocytoma clinical trial landscape.

Anaplastic Astrocytoma Overview

Anaplastic Astrocytoma is a rare malignant brain tumor. Astrocytomas are tumors that develop from certain star-shaped brain cells called astrocytes. Astrocytes and similar cells form tissue that surrounds and protects other nerve cells found within the brain and spinal cord.

Find out more about Anaplastic Astrocytoma Treatment Drugs @ Drugs for Anaplastic Astrocytoma Treatment

Anaplastic Astrocytoma Emerging Drugs Profile

• Eflornithine: Orbus Therapeutics
• Zotiraciclib: Cothera Bioscience

Anaplastic Astrocytoma Pipeline Therapeutics Assessment

There are approx. 15+ key companies which are developing the therapies for Anaplastic Astrocytoma. The Anaplastic Astrocytoma companies which have their Anaplastic Astrocytoma drug candidates in the most advanced stage, i.e. phase III include, Orbus Therapeutics.

Learn more about the emerging Anaplastic Astrocytoma Pipeline Therapies @ Anaplastic Astrocytoma Clinical Trials Assessment

Scope of the Anaplastic Astrocytoma Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Anaplastic Astrocytoma Companies- Orbus Therapeutics, Cothera Bioscience, Celgene, Wayshine Biopharm Inc., OncoSynergy, AEterna Zentaris, Oncoceutics, DNAtrix, Novartis Pharmaceuticals, Curis, Inc., Everfront Biotech Co., Ltd., Pfizer, Kazia Therapeutics Limited, Bayer, Geneos Therapeutics, Cellix Bio, Mustang Bio, Deciphera Pharmaceuticals, Aveta Biomics, and others.
• Anaplastic Astrocytoma Pipeline Therapies- Eflornithine, Lomustine, Erlotinib, Sunitinib Malate, Bononophenylalanine (BPA)-based BNCT, Leflunomide, LS11 (talaporfin sodium), Temozolomide, Semustine, CC-90010, AP 12009 10 µM, TG02, AMG 595, Valacyclovir, and others.

Dive deep into rich insights for new drugs for Anaplastic Astrocytoma Treatment, Visit @ Anaplastic Astrocytoma Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Anaplastic astrocytoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Anaplastic astrocytoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Eflornithine: Orbus Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug name: Company name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. GT-10: Geneos Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CLX-ONC-643: Cellix Bio
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Anaplastic astrocytoma Key Companies
21. Anaplastic astrocytoma Key Products
22. Anaplastic astrocytoma- Unmet Needs
23. Anaplastic astrocytoma- Market Drivers and Barriers
24. Anaplastic astrocytoma- Future Perspectives and Conclusion
25. Anaplastic astrocytoma Analyst Views
26. Anaplastic astrocytoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting